Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Agency

All agencies FDA (Food)FDA (Drugs)FDA (Devices)USDA FSIS CPSC NHTSA EPA

9351–9375 of 11860

SevereFDA (Drugs)·D-595-2015·2015-04-29
Attix Pharmaceuticals Recalls Clomipramine HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Clomipramine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Clomipramine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-918-2015·2015-04-29
Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-642-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline Hyclate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline Hyclate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline Hyclate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-555-2015·2015-04-29
Attix Pharmaceuticals Recalls Calcipotriene Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Calcipotriene active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Calcipotriene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-919-2015·2015-04-29
Attix Pharmaceuticals Recalls Terbinafine Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Terbinafine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Terbinafine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-730-2015·2015-04-29
Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-877-2015·2015-04-29
Attix Pharmaceuticals Recalls Reserpine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling reserpine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Reserpine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-775-2015·2015-04-29
Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-895-2015·2015-04-29
Simvastatin API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Simvastatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Simvastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-575-2015·2015-04-29
Attix Pharmaceuticals Recalls Chloramphenicol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chloramphenicol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Chloramphenicol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-668-2015·2015-04-29
Attix Pharmaceuticals Recalls Everolimus API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of everolimus active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Everolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-747-2015·2015-04-29
Attix Pharmaceuticals Recalls Lamotrigine Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling lamotrigine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Lamotrigine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-719-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxocobalamin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydroxocobalamin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-521-2015·2015-04-29
Amphotericin B Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Amphotericin B active pharmaceutical ingredient due to potential cross contamination with penicillin during repackaging.
Product
Amphotericin B active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-818-2015·2015-04-29
Attix Pharmaceuticals Recalls Nitazoxanide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Nitazoxanide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Nitazoxanide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-843-2015·2015-04-29
Pioglitazone HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Pioglitazone HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pioglitazone HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-562-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-661-2015·2015-04-29
Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-606-2015·2015-04-29
Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-709-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Ophthalmic Grade) because it was repackaged in a facility with penicillin products, posing a cross-contamination risk.
Product
Hyaluronic Acid Sodium Salt (Ophthalmic Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-559-2015·2015-04-29
Attix Pharmaceuticals Recalls Capecitabine Due to Penicillin Cross Contamination
Attix Pharmaceuticals is recalling capecitabine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Capecitabine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-710-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-549-2015·2015-04-29
Attix Pharmaceuticals Recalls Bromocriptine Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Bromocriptine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Bromocriptine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-622-2015·2015-04-29
Attix Pharmaceuticals Recalls Desoximetasone Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Desoximetasone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Desoximetasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-565-2015·2015-04-29
Attix Pharmaceuticals Recalls Carvedilol API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carvedilol active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.
Product
Carvedilol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide

How to read this listing

Filters

9351–9375 of 11860